A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure: Design and rationale of the MONITOR HF multicentre randomised clinical trial

J. J. Brugts*, J. F. Veenis, S. P. Radhoe, G. C.M. Linssen, M. van Gent, C. J.W. Borleffs, J. van Ramshorst, P. van Pol, R. Tukkie, R. F. Spee, M. E. Emans, W. Kok, V. van Halm, L. Handoko, S. L.M.A. Beeres, M. C. Post, E. Boersma, M. J. Lenzen, O. C. Manintveld, H. KoffijbergP. van Baal, M. Versteegh, T. D. Smilde, L. van Heerebeek, M. Rienstra, A. Mosterd, P. P.H. Delnoy, F. W. Asselbergs, H. P. Brunner-La Rocca, R. A. de Boer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
16 Downloads (Pure)

Abstract

Background: Assessing haemodynamic congestion based on filling pressures instead of clinical congestion can be a way to further improve quality of life (QoL) and clinical outcome by intervening before symptoms or weight gain occur in heart failure (HF) patients. The clinical efficacy of remote monitoring of pulmonary artery (PA) pressures (CardioMEMS; Abbott Inc., Atlanta, GA, USA) has been demonstrated in the USA. Currently, the PA sensor is not reimbursed in the European Union as its benefit when applied in addition to standard HF care is unknown in Western European countries, including the Netherlands. Aims: To demonstrate the efficacy and cost-effectiveness of haemodynamic PA monitoring in addition to contemporary standard HF care in a high-quality Western European health care system. Methods: The current study is a prospective, multi-centre, randomised clinical trial in 340 patients with chronic HF (New York Heart Association functional class III) randomised to HF care including remote monitoring with the CardioMEMS PA sensor or standard HF care alone. Eligible patients have at least one hospitalisation for HF in 12 months before enrolment and will be randomised in a 1:1 ratio. Minimum follow-up will be 1 year. The primary endpoint is the change in QoL as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Secondary endpoints are the number of HF hospital admissions and changes in health status assessed by EQ-5D-5L questionnaire including health care utilisation and formal cost-effectiveness analysis. Conclusion: The MONITOR HF trial will evaluate the efficacy and cost-effectiveness of haemodynamic monitoring by CardioMEMS in addition to standard HF care in patients with chronic HF. Clinical Trial Registration number NTR7672.

Original languageEnglish
Pages (from-to)16-26
Number of pages11
JournalNetherlands heart journal
Volume28
Issue number1
Early online date10 Dec 2019
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • CardioMEMS
  • e‑Health
  • Heart failure
  • Telemonitoring
  • Therapy
  • Trial

Fingerprint Dive into the research topics of 'A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure: Design and rationale of the MONITOR HF multicentre randomised clinical trial'. Together they form a unique fingerprint.

  • Cite this